The story of Viagra, and its developer copyright, presents a intriguing case study for investors. At first a blockbuster drug, yielding billions in income, its intellectual property lapse created a deluge of knock-off medications, significantly impacting its dominance. While certain firms may seek to capitalize on male sexual dysfunction, the pr… Read More